Phaseline

Companies › Alnylam Pharmaceuticals

Alnylam Pharmaceuticals: clinical trials, targets and expected readouts

15 active drug programs in 19 registered trials: 10 Phase 1, 5 Phase 2, 4 Phase 3; Neurology, Cardiovascular, Metabolic and endocrine, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vutrisiran
Transthyretin mRNA rnai inhibitor
TTRPhase 3Transthyretin Amyloidosis (ATTR) With CardiomyopathyJan 2027
Nucresiran (ALN-TTRSC04)
TTR synthesis inhibitor; siRNA targeting TTR mRNA
TTRPhase 3Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy; Transthyretin Amyloidosis With CardiomyopathyDec 2027
Zilebesiran
Small interfering RNA (siRNA) targeting angiotensinogen (AGT) mRNA
AGTPhase 3High Risk Cardiovascular DiseaseSep 2030
ALN-4324
APOC3 antisense oligonucleotide
–Phase 2Type 2 Diabetes Mellitus (T2DM); Obese or Overweight Healthy VolunteersMay 2027
ALN-6400
unclear - likely RNA interference or RNAi-based therapeutic for VWD and HMB
–Phase 2Von Willebrand Disease (VWD); Hereditary Hemorrhagic TelangiectasiaJun 2027
ALN-APP
siRNA targeting amyloid precursor protein (APP)
APPPhase 2Cerebral Amyloid Angiopathy; Early-Onset Alzheimer DiseaseAug 2027
ALN-AGT01 RVR
RNA interference therapeutic targeting AGT; reduces angiotensinogen production
AGTPhase 2HypertensionApr 2028
Mivelsiran
Antisense oligonucleotide targeting APP mRNA
APPPhase 2Down Syndrome-Associated Alzheimer's Disease (DS-AD)May 2030
ALN-4285–Phase 1Healthy VolunteersDec 2026
ALN-2232
RNAi therapeutic targeting APOB
–Phase 1ObesityApr 2027
ALN-4915–Phase 1Healthy VolunteersJul 2027
ALN-BCAT
BCAT1 inhibitor
BCAT1Phase 1Advanced Hepatocellular CarcinomaSep 2027
ALN-6222–Phase 1ObesityDec 2027
ALN-HTT02
HTT-targeting siRNA (RNAi therapeutic targeting huntingtin mRNA)
HTTPhase 1Huntington's DiseaseJul 2028
ALN-5288
apolipoprotein B (APOB) mRNA silencing agent
APOBPhase 1Alzheimer's DiseaseMar 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07295717ALN-4285Phase 1Healthy VolunteersOtherDec 2026
NCT04153149VutrisiranPhase 3Transthyretin Amyloidosis (ATTR) With CardiomyopathyCardiovascularJan 2027
NCT07463846ALN-2232Phase 1ObesityMetabolic and endocrineApr 2027
NCT07465224ALN-4324Phase 2Type 2 Diabetes Mellitus (T2DM)Metabolic and endocrineMay 2027
NCT07575308ALN-6400Phase 2Von Willebrand Disease (VWD)HematologyJun 2027
NCT07535606ALN-4915Phase 1Healthy VolunteersOtherJul 2027
NCT06393712ALN-APPPhase 2Cerebral Amyloid AngiopathyNeurologyAug 2027
NCT06845202ALN-4324Phase 1Obese or Overweight Healthy VolunteersMetabolic and endocrineAug 2027
NCT06600321ALN-BCATPhase 1Advanced Hepatocellular CarcinomaOncologySep 2027
NCT07624071ALN-6222Phase 1ObesityMetabolic and endocrineDec 2027
NCT07223203Nucresiran (ALN-TTRSC04)Phase 3Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyNeurologyDec 2027
NCT06659640ALN-6400Phase 1Hereditary Hemorrhagic TelangiectasiaCardiovascularJan 2028
NCT07553442ALN-AGT01 RVRPhase 2HypertensionCardiovascularApr 2028
NCT06585449ALN-HTT02Phase 1Huntington's DiseaseNeurologyJul 2028
NCT05231785ALN-APPPhase 1Early-Onset Alzheimer DiseaseNeurologyJan 2029
NCT07214727ALN-5288Phase 1Alzheimer's DiseaseNeurologyMar 2030
NCT07636811MivelsiranPhase 2Down Syndrome-Associated Alzheimer's Disease (DS-AD)NeurologyMay 2030
NCT07052903Nucresiran (ALN-TTRSC04)Phase 3Transthyretin Amyloidosis With CardiomyopathyCardiovascularMay 2030
NCT07181109ZilebesiranPhase 3High Risk Cardiovascular DiseaseCardiovascularSep 2030

From the company's SEC filings

Cash and short-term investments of $3.6bn on 2026-09-30; operating cash flow positive

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

APP (2) TTR (2) AGT (2) APOB (1) HTT (1) BCAT1 (1)

Companies with the same targets

Roche AstraZeneca Eli Lilly Eisai Acumen Pharmaceuticals JYAMS PET Research & Development Amyloid Solution HTA Nuravax Novo Nordisk

Companies built like this

Ionis Pharmaceuticals Biogen Vertex Pharmaceuticals BioMarin Pharmaceutical Arrowhead Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.